{"id":"NCT02046603","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","officialTitle":"Open-Label, Phase IIIb Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab Monotherapy or Combination Therapy With Methotrexate (MTX) or Other Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Patients With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-Tumour Necrosis Factor (Anti-TNF) Biologic Agent","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-04","primaryCompletion":"2016-08-04","completion":"2016-08-04","firstPosted":"2014-01-28","resultsPosted":"2018-12-07","lastUpdate":"2018-12-07"},"enrollment":162,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab","otherNames":["RoActemra, Actemra"]},{"type":"DRUG","name":"DMARDs","otherNames":[]},{"type":"DRUG","name":"Oral Corticosteroids","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]}],"arms":[{"label":"Tocilizumab Monotherapy","type":"EXPERIMENTAL"},{"label":"Tocilizumab in Combination With Methotrexate or Other DMARDs","type":"EXPERIMENTAL"}],"summary":"This open-label study will evaluate the efficacy and safety of tocilizumab as monotherapy or in combination with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in participants with active rheumatoid arthritis (RA) and an inadequate response to current non-biologic DMARD therapy or the first anti-tumour necrosis factor (anti-TNF) agent. Participants will receive tocilizumab 162 milligrams (mg) subcutaneously once a week for 52 weeks.","primaryOutcome":{"measure":"Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 2","timeFrame":"Baseline, Week 2","effectByArm":[{"arm":"Tocilizumab Monotherapy","deltaMin":5.52,"sd":1.014},{"arm":"Tocilizumab in Combination With Methotrexate or Other DMARDs","deltaMin":5.53,"sd":1.257}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":38,"countries":["United Kingdom"]},"refs":{"pmids":["31431998","30649524","29244149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":21},"commonTop":["Nasopharyngitis","Diarrhoea","Alanine aminotransferase increased","Lower respiratory tract infection","Oropharyngeal pain"]}}